Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+ HER2+ Advanced Breast Cancer Patients

  • STATUS
    Recruiting
  • days left to enroll
    77
  • participants needed
    95
  • sponsor
    Yonsei University
Updated on 26 January 2021
cancer
ejection fraction
estrogen
breast cancer
lapatinib
endocrine therapy
oophorectomy
metastasis
neutrophil count
hormone therapy
pertuzumab
liver metastasis
advanced breast cancer
HER2
trastuzumab
tamoxifen
stage iv breast cancer
estrogen receptor
abemaciclib
cish
palbociclib
her2/neu-positive breast cancer
taxane
letrozole
chromogenic in situ hybridization
ribociclib

Summary

Survival benefit and quality of life are two key elements that should be kept in mind in the treatment of metastatic breast cancer. In this regards, endocrine therapy (ET) is strongly recommended in hormone receptor (HR) positive patients unless there is visceral crisis even though there is no concrete evidence that it is better than chemotherapy in terms of survival.

HER2 positive breast cancer is a subtype of breast cancer that showed the greatest improvement in terms of survival during the last decade due to trastuzumab based therapy. Recently, taxane and HER2 directed doublet including trastuzumab and pertuzumab (THP) is considered as standard of therapy based upon randomized phase 3 clinical trial (CLEOTATRA).

HER2 positive breast cancer can be divided into HER2 enriched subgroup (HR-HER2+) and luminal B subgroup (HR+HER2+) in biologic viewpoint because they are distinctly different subgroups in gene expression analysis. Accordingly, we are currently treating biologically different subtypes in a same way, which is CTx and anti-HER2 combination therapy (THP).

Luminal HER2+ subgroup has actually been tested with endocrine therapy (ET) and anti-HER2 therapy showed better PFS than ET alone (TAnDEM trial and trial comparing lapatinib plus letrozole versus letrozole alone) [2],[3] confirming existence of cross talk between ER and HER2 pathways in clinical setting. However, the combination regimen between ET and anti-HER2 therapy is not widely used in current practice in ER+HER2+ MBC patients because PFS seemed to be relatively shorter compared with chemotherapy based combination with anti-HER2 therapy even though several guidelines recommend it to be used as an initial treatment unless there is visceral crisis as they recommended ET alone first in ER+HER2- MBC (NCCN 2018).

Recently, various CDK4/6 inhibitors including palbociclib, abemaciclib, and ribociclib were approved by FDA based on the clinical trial results demonstrating prolonged PFS over ET alone when it was combined with ET in ER+ advanced breast cancer [4]. In PALOMA 2 biomarker study, it was beneficial regardless of ER and Ki67 expression status.

Reflecting quite durable PFS prolongation (10 month in PALOMA2) shown in ER+ disease (luminal A and luminal B subtype except HR+HER2+ patients) with CDK4/6 inhibitor on top of ET, the hypothesis of this trial is whether CDK4/6 inhibitor could prolong survival in luminal HER2 breast cancer as it did in ER+HER2-patients. In preclinical study, palbociclib showed activity in not only ER+ cell lines but also HER2 positive cell lines [5]. Also, in phase Ib trial, a CDK4/6 inhibitor from Lilly, abemaciclib showed acceptable toxicity with endocrine therapy or trastuzumab with response rate of around 20%.

Hence, as of today, it could be justified and warranted to conduct a prospective trial of ribocicib+letrozole+trastuzumab in order to take a look at its efficacy and toxicity in HR+HER2 + advanced breast cancer.

Description

This trial is performed in a multicenter, single-group, and phases IB and II clinical trial.

This is a single-group clinical trial of the effects of ribociclib, letrozole and trastuzumab in postmenopausal women with HR+, HER2+ advanced breast cancer. This trial consists of two parts. The first part is a phase IB study of increasing the dose of ribociclib from 200mg to 600mg in combination with letrozole 2.5mg and trastuzumab (8mg/kg followed by 6mg/kg every 3 weeks). In phase IB study, three to six patients will be enrolled for each dose group.

When the IB phase ends, patient enrollment will be discontinued for intermediate safety analysis, and after DLT analysis will determine recommended phase II phase II part will be started. The recommended phase II dose of ribocicib determined in phase IB part with ribociclib and trastuzumab (8mg/kg followed by 6mg/kg every 3 weeks) will be administered. Treatment is discontinued in the following cases.

  • Progression of disease
  • Uncontrolled toxicity
  • Patient's death
  • Withdrawal of consent In phase II part, 61 patients will be enrolled and the first 20 patients will be analyzed for run-in phase to confirm the safety of the therapy.

Regardless of treatment cycle, the disease will be evaluated in the same manner as the method used at the time of registration at intervals of 8 weeks for the first 18 months and at intervals of 12 weeks after that. If the progress of the disease is clinically suspected, additional tests can be performed

Details
Condition Metastatic Breast Cancer, HER2 Positive Breast Cancer, Postmenopausal, Stage IV Breast Cancer, her2/neu-positive breast cancer, her2-positive breast cancer
Treatment Ribociclib, Trastuzumab, Letrozole
Clinical Study IdentifierNCT03913234
SponsorYonsei University
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients aged 19 years
Women with advanced (loco-regionally recurrent or metastatic) breast cancer not amenable for curative therapy
Histologically and/or cytologically confirmed estrogen receptor positive and/or progesterone receptor positive breast cancer
HER2 positive breast cancer (IHC 3+ or IHC 2+ and FISH, SISH or CISH+)
Postmenopausal patient defined as either one of the following
Prior bilateral ovariectomy
Age 60 years old
Age <60 years and amenorrhea over 12 months (without chemotherapy, tamoxifen, toremifene or ovarian inhibition), FSH and estradiol are in the postmenopausal range according to local normal range
Patients who were not previously treated with systemic treatment for advanced / metastatic breast cancer
ECOG performance status 0 or 1
Measurable or evaluable lesion according to RECIST v1.1
Normal organ function defined as
ANC (absolute neutrophil count) 1.5 109/L
Platelet 100 109/L
Serum Hb 9.0 g/dL
INR 1.5
Serum creatinine 1.5 X ULN
ALT & ALT < 2.5 X ULN (in the absence of liver metastasis) or ALT & ALT < 5 X ULN (with liver metastasis)
Total serum bilirubin < 1.5 X ULN
Left Ventricular Ejection Fraction (LVEF) within normal range
Voluntary agreement on clinical trials

Exclusion Criteria

Patients who have previously received CDK4 / 6 inhibitors or who have received other systemic treatments for advanced / metastatic breast cancer (Previous neo-adjuvant of adjuvant trastuzumab or aromatase inhibitor is not allowed, unless
Disease free interval was more than 12 months from the last dose of adjuvant trastuzumab or
Adjuvant aromatase inhibitor was administered more than 2 years)
Inflammatory breast cancer
Central nervous system metastasis
Active cardiac disease or a history of cardiac dysfunction including any of the following (Congestive heart failure within 6 months, history of myocardial infarction, unstable angina pectoris, or QTc prolongation on electrocardiogram)
Gastrointestinal absorption disorders that interfere with drug absorption
Patients who is currently receiving medications that can prolong QT intervals (QTc>450msec) on ECG or that can cause torsades de pointes
Patients with severe visceral metastasis on enrolment who are not indicated with hormone treatment
Serious surgical treatment within 14 days prior to study treatment
Radiotherapy within 21 days prior to study treatment
Serious medical comorbidities
Concurrent malignancy or malignancy within 3 years of study participation, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note